Search results
Results from the WOW.Com Content Network
The COVID-19 pandemic in Germany has resulted in 38,437,856 [1] confirmed cases of COVID-19 and 174,979 [1] deaths. During the pandemic, the German government received advice from several scientific bodies including the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute, the German National Academy of Sciences Leopoldina, and the German Ethics Council.
Europe clears J&J's (JNJ) COVID-19 vaccine. Eli Lilly (LLY), Merck (MRK) and Glaxo (GSK) give update on their COVID-19 antibody/antiviral candidates. Pharma Stock Roundup: EU Nod for J&J COVID-19 ...
The COVID-19 vaccination campaign in Germany began on 26 December 2020. [ 2 ] As of 16 December 2021 [update] , 60,679,186 people have received at least one dose (73% of total population), while 58,174,724 people have been fully vaccinated (70% of total population). [ 3 ]
Tellingly, Germany's statistical office publishes more than 20 monthly datasets for the industrial sector, including very detailed figures for the automotive, chemical and pharmaceutical sub-segments.
Three ways to sign in for contact tracing during the COVID-19 pandemic in Germany. From May 2020 [49] until late 2021, the so-called "seven-day incidence" was the main criterion for determining restrictions to fight the pandemic. The seven-day incidence is measured at a locality (district, state or federal level) as the average number of new ...
Both Germany and France announced new nationwide lockdowns on Wednesday as Europe enters a deadly new phase of the coronavirus pandemic. Chancellor Angela Merkel says German officials have agreed ...
The effective reproduction number or reproduction rate, symbolised with R e, is a rate of how many more people are infected from a positive COVID-19 case.In order to suppress an outbreak, the reproduction rate must be constantly below 1, which means each positive case infects less than one person.
Beyond CVnCoV, CureVac has also partnered with GlaxoSmithKline (GSK) to develop a new generation of mRNA-based COVID-19 vaccines. Human testing is due in late 2021. [40] [needs update] The start of the phase 1 study with the product candidate CV2CoV, which was announced for the fourth quarter of 2021, had to be postponed to the first quarter of ...